Iskender, B. Et Al. 2016. Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?. TUMOR BIOLOGY , vol.37, no.2 , 1967-1981.

Iskender, B., Izgi, K., Sakalar, C., & CANATAN, H., (2016). Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?. TUMOR BIOLOGY , vol.37, no.2, 1967-1981.

Iskender, BANU Et Al. "Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?," TUMOR BIOLOGY , vol.37, no.2, 1967-1981, 2016

Iskender, BANU İ. Et Al. "Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?." TUMOR BIOLOGY , vol.37, no.2, pp.1967-1981, 2016

Iskender, B. Et Al. (2016) . "Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?." TUMOR BIOLOGY , vol.37, no.2, pp.1967-1981.

@article{article, author={BANU İSKENDER İZGİ Et Al. }, title={Priming hMSCs with a putative anti-cancer compound, myrtucommulone-a: a way to harness hMSC cytokine expression via modulating PI3K/Akt pathway?}, journal={TUMOR BIOLOGY}, year=2016, pages={1967-1981} }